Treatment with antiepileptic therapy for 3 months for children with GLUT1 DS-resistant epilepsy aged 3–9 years [125], serum adiponectin level increases in the KD group (some of whom are also treated with other antiepileptic agents), compared with VPA monotherapy. The gene discussed is ADIPOQ; the disease is epilepsy.